ArticleiScience2026
Dimensionality-modulated generative AI for safe biomedical dataset augmentation.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Generative AI can expand small biomedical datasets but may amplify noise and distort statistical relationships. We developed genESOM, a framework integrating an error control system into a generative AI method based on emergent self-organizing maps. By separating structure learning from data synthesis, genESOM enables dimensionality modulation and injection of engineered diagnostic features, i.e., permuted versions of real variables, as negative controls that track feature importance stability. A data-driven stopping criterion halts augmentation when error inflation begins, limiting overfitting. Validation across two artificial and six biomedical datasets, including preclinical and clinical domains, showed that moderate augmentation (one synthetic sample per original) preserved variable ranking and yielded strong negative correlations (Kendall's tau: -0.53 to -0.85) between statistical significance and feature selection frequency. Excessive augmentation disrupted these relationships. Moderate preclinical augmentation safely doubled sample sizes without compromising analytical reliability and supported up to 50% reductions in laboratory animal use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.